Common Sense Oncology

Cancer trials increasingly measure quality of life. But are we asking—and answering—the questions patients really need answered?

What are the chances a treatment will make me feel better or worse? How will it affect my ability to function? How long might those effects last? And how do we weigh quality of life against the potential benefits of treatment?

Join Drs. Madeline Pe, Ian Tannock, and Michael Brundage on November 13 at 11 a.m. ET for a high-level conversation about making quality-of-life evidence more meaningful for patients, followed by an extended panel discussion and Q&A.

Register here: us02web.zoom.us/webinar/regist…

#CommonSenseOncology #CancerCare @MichelleTregear

Join CSO on November 16th for a critical appraisal of the RASolute 302 trial, followed by a discussion of how the pricing of daraxonrasib will impact patient access.

Where: Online (Zoom)
When: Monday, November 16, 2026 at 2:00 pm (EST) / 1:00 pm (CST) / 12:00 pm (MST)
Speakers: Dr. Ian Tannock, Dr. Chris Booth, Dr. Sharlene Gill, Carolyn Taylor, Dr. Ramy Sedhom

Register now: tinyurl.com/hr3jsnxc

#CommonSenseOncology #CancerCare #Daraxonrasib

The CSO Symposium at Kenya Society of Haematology & Oncology (KESHO) is taking place on Thursday, November 19th in Mombasa, Kenya! Register for the conference here: kesho-kenya.org/conference/

#CommonSenseOncology #CancerCare

CSO and oncologists across Canada are speaking out about escalating cancer drug costs after the recent U.S. pricing announcement for the new pancreatic cancer drug daraxonrasib. The list price of CAD$56,300 per month means it will be inaccessible to many patients and health systems, and risks turning a breakthrough treatment into an unfulfilled promise to cancer patients.

Watch the segment on daraxonrasib from CBC's The National for more: tinyurl.com/aaecm4nv

#CommonSenseOncology #CancerCare

Join CSO this Thursday, November 5th online for London Global Cancer Week! Register here: tinyurl.com/5n7m9be8

#CommonSenseOncology #CancerCare